Navigation Links
Oncothyreon to present at BIO Investor Forum 2008
Date:10/24/2008

SEATTLE, Oct. 24 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the 7th Annual BIO Investor Forum in San Francisco on Friday, October 31, 2008 at 8:00 a.m. Pacific Time.

A live and archived webcast of Dr. Kirkman's presentation can be accessed at http://www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
2. Oncothyreon announces prioritization plan for development programs
3. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
4. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
5. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
6. Oncothyreon to receive milestone payment
7. Oncothyreon Reports First Quarter 2008 Financial Results
8. Oncothyreon files investigational new drug application for PX-866 oncology compound
9. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
10. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
11. Oncothyreon announces effectiveness of shelf registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group ... an Asia-Pacific Symposium as other research and development initiatives for potential stem cell protocol ... top Global Stem Cells Group executives began meeting to establish a working agenda and ...
(Date:4/26/2016)... ... April 27, 2016 , ... ... Christie LLP as an associate in the firm’s Intellectual Property practice group. , ... and electromechanical patent applications. He has an electrical engineering and computer engineering background, ...
(Date:4/26/2016)... Heidelberg, Baden-Württemberg (PRWEB) , ... April 26, 2016 ... ... production of laser lithography systems, announces the latest technology innovation for its Volume ... to fulfill tomorrow’s demand for production of advanced photomasks as well as a ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a ... round of financing. Healthy investor interest drove significant oversubscription of the original $1.5M ... known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, ...
Breaking Biology Technology:
(Date:3/3/2016)... March 3, 2016  2016FLEX, organized by FlexTech, ... highlighting advancements in flexible, hybrid and printed electronics. ... attendance - have gathered for short courses, technical ... of electronics. The Flex Conference celebrates its 15 ... companies, R&D organizations, and universities contributing to the ...
(Date:3/2/2016)... 2, 2016 ... of the  "Global Biometrics Market in Hospitality ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics market ... a CAGR of around 27%   ... announced the addition of the  "Global Biometrics ...
(Date:3/1/2016)... , March 1, 2016 ... the addition of the  "Global Biometric ...  report to their offering. --> ... addition of the  "Global Biometric Access ... to their offering. --> ...
Breaking Biology News(10 mins):